Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Investor Presentation (September 2012)

32 slides from Questcor Pharmaceuticals's investor presentation, Sep 10, 2012

  1. Slide 1: September 2012

    September 2012 Exhibit 99.1 September 2012 NASDAQ: QCOR

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa

  3. Slide 3: A biopharmaceutical company focused on serious autoimmune and inflammatory disorders

    A biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders Questcor 3 A biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders

  4. Slide 4: Questcor Overview

    4 Flagship Product: • Profitable, cash flow positive, $133M** in cash, debt-free • 19 approved indications Key Markets*: • Nephrotic Syndrome, Multiple Sclerosis, Infantile Spasms, Dermatomyositis/Polymyositis • Several billion dollar market opportunity Strategy: • Grow Acthar sales in each key mark

  5. Slide 5: Growth in Shipped Vials - Quarterly

    Growth in Shipped Vials - Quarterly 5 1,000 2,000 3,000 4,000 5,000 Shipped Vials - Quarterly 4,500 3,500 2,500 1,500

  6. Slide 6: Q2-2012 Financial Results

    6 Q2 – 2012 Q2 – 2011 Q2-2012 Financial Results • Second quarter vials shipped: 4,710 • Second quarter cash flow from operations: $43.2M • Channel inventory estimated to be within the normal range • Medicaid reserves continue to appear adequate • 3.7M shares repurchased during Q2-2012 Record Net Sal

  7. Slide 7: Paid Rxs July and August 2012 (estimated)

    Paid Rxs July and August 2012 (estimated) – 5 RA/Lupus Paid Rxs in July - August – Script counts exclude fully rebated due to 100% Medicaid rebate (Medicaid rebate likely to decrease in 2013) Shipped 2,190 vials in August 2012 – Compares to 4,710 vials in Q2-12 – Channel inventory level remained wit

  8. Slide 8: Growth in Shipped Vials – Monthly

    Growth in Shipped Vials – Monthly 8 1,000 1,500 2,000 2,500 Shipped Vials - Monthly

  9. Slide 9: Questcor Strategy - Pursue Acthar Markets

    9 Questcor Strategy - Pursue Acthar Markets Multiple Sclerosis (MS) Infantile Spasms (IS) Rheumatology Nephrotic Syndrome (NS)

  10. Slide 10: Acthar and Nephrotic Syndrome (NS)

    10 • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Acthar is approved “to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic t

  11. Slide 11: NS Scripts-Strong Continued Growth

    11 Paid Rxs NS Scripts-Strong Continued Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the f

  12. Slide 12: Monthly NS Scripts History

    12 Monthly NS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indications associated with NS, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition

  13. Slide 13: Acthar and Multiple Sclerosis (MS)

    13 Neurodegenerative disorder Acute treatment for relapses Acthar and Multiple Sclerosis (MS) ACTHAR is approved for MS exacerbations, without reference to first line or second line use but is generally positioned as second line as a matter of marketing strategy. See http://www.acthar.com/files/Acth

  14. Slide 14: MS Scripts-Record of Consistent Growth

    MS Scripts-Record of Consistent Growth 14 Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative

  15. Slide 15: Monthly MS Scripts History

    15 Monthly MS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the

  16. Slide 16: Acthar and Infantile Spasms (IS)

    16 • Devastating, refractory form of childhood epilepsy • Unsuccessful treatment may leave infant with permanent developmental disabilities • Ultra-rare orphan disorder • Acthar currently used to treat 40-50% of IS patients • Targeting select institutions Acthar and Infantile Spasms (IS) • Devastati

  17. Slide 17: Rheumatology

    17 • 4 key indications on the Acthar label* – Dermatomyositis/Polymyositis (DM/PM) – Systemic lupus erythematosus (Lupus) – Psoriatic arthritis – Rheumatoid arthritis • High unmet need; difficult to treat • Serious health risk if unsuccessfully treated • Significant patient population (multi $B oppo

  18. Slide 18: Rheumatology: Estimated Patient Populations

    18 Rheumatology: Estimated Patient Populations* Indication Total Estimated US Population Estimated Target Acthar Population *Questcor estimates Dermatomyositis/Polymyositis 66K ~26K Systemic Lupus Erythematosus 250K ~50K-100K Rheumatoid Arthritis 1.3M ~50K Psoriatic Arthritis 500K ~40K Juvenile Rheu

  19. Slide 19: How Does Acthar Work?

    19 How Does Acthar Work? • Acthar treats autoimmune conditions across a variety of organ systems (CNS, kidney, etc.) • Acthar appears to modulate the immune system and associated inflammatory response through binding to melanocortin receptors • The primary melanocortin peptide (ACTH) in Acthar binds

  20. Slide 20: Biosimilar Pathway Difficult/Impossible

    20 • Difficult/impossible to reverse engineer Acthar – Not well characterized • Complex pharmacology – Not well characterized • Clinical trial(s) likely required • Branded competition in specific indication possible at some point in the future Biosimilar Pathway Difficult/Impossible • Difficult/impo

  21. Slide 21: Understanding Acthar: science of how it works and clinical use

    21 • Understanding the biological properties of Acthar – Specific biochemical pathways, cells, and tissues – Immunomodulation and anti-inflammatory • On-label indications – Proteinuria in NS, MS flares, Lupus • New indications – Nephrology (eg, diabetic nephropathy) – Indications with autoimmune/inf

  22. Slide 22: Understanding Acthar: clinical use

    22 • Clinical use of Acthar – Nonclinical research – Clinical research • On-label indications – Proteinuria in nephrotic syndrome (NS), multiple sclerosis (MS) flares, infantile spasms, lupus • Off-label indications – Diabetic nephropathy, traumatic brain injury, autism, MS maintenance treatment Aca

  23. Slide 23: Strategic Plan - Focus on the Embedded Pipeline in Acthar

    23 • Grow Nephrotic Syndrome business (107 reps) • Grow Multiple Sclerosis business (58 reps) • Continue to Support Infantile Spasm indication • Build Rheumatology therapeutic usage (12 reps) • Develop other markets for Acthar Strategic Plan- Focus on the Embedded Pipeline in Acthar • Grow Nephrotic

  24. Slide 24: Share Repurchases: 21.4 Million Shares

    24 • 2.2 Million Preferred share buyback • 19.2 Common share buyback • $322 million returned to shareholders in stock buybacks – Average repurchase price per share: $15.02 • 58.4 million shares currently outstanding • 5.0 million shares added to buyback authorization • 3.2 million shares remain on b

  25. Slide 25: 2012 Repurchase Activity

    25 • 6.0M shares repurchased during 2012, driven by: – Sales/EPS increase – NS market traction – Sales force expansion – Rheumatology opportunity 2012 Repurchase Activity Repurchased shares significantly improved EPS Q2-2012 EPS accretion from share repurchase from 2008 through 6/30/2012: 30% • 6.0M

  26. Slide 26: Investment Highlights

    26 Investment Highlights Acthar has sustainable competitive Acthar has sustainable competitive advantages advantages Acthar is approved for 19 indications-many Acthar is approved for 19 indications-many in large markets with sizable unmet need in large markets with sizable unmet need Sales in NS and

  27. Slide 27: September 2012

    September 2012 NASDAQ: QCOR September 2012 NASDAQ: QCOR

  28. Slide 28: Acthar History

    28 Acthar History 1950 2000 2010 1968-1973 DESI review = steroid label > 50 indications 1950 1978 MS indication added 2000 2001-2003 Questcor acquires Acthar Gel (MR), FDA approves manufacturing 2010 Infantile spasms approved, Label modernized steroid & 19 indications 2009-Present Expanding Acthar G

  29. Slide 29: ACTH is a Melanocortin Peptide Derived from POMC

    29 ACTH is a Melanocortin Peptide Derived from Pro-opiomelanocortin (POMC) in the Pituitary

  30. Slide 30: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes

    30 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC1R Podocytes Renal Mesangial Cells Endothelial Cells (Glomerular, Tubular, Vascular) Tubular Epithelial Cells Macrophages Melanocyt

  31. Slide 31: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes

    31 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC3R CNS Macrophages MC4R Podocytes Renal Mesangial Cells (?) Endothelial Cells (Glomerular, Tubular) Tubular Epithelial Cells CNS MC

  32. Slide 32: MOA of Acthar in NS

    32 MOA of Acthar in NS Adapted From Gong 2011 Acthar, Melanocortin Peptides Acthar, Melanocortin Peptides

Questcor Pharmaceuticals — Investor Presentation (September 2012) on 6ix